{"organizations": [], "uuid": "70dae70a02c1f0c8e4725967e7962261032a3bbf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regenxbio-enters-strategic-partner/brief-regenxbio-enters-strategic-partnership-with-fujifilm-diosynth-biotechnologies-idUSFWN1PI18C", "country": "US", "domain_rank": 408, "title": "BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T05:49:00.000+02:00", "replies_count": 0, "uuid": "70dae70a02c1f0c8e4725967e7962261032a3bbf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regenxbio-enters-strategic-partner/brief-regenxbio-enters-strategic-partnership-with-fujifilm-diosynth-biotechnologies-idUSFWN1PI18C", "ord_in_thread": 0, "title": "BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fujifilm diosynth biotechnologies", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "regenxbio inc", "sentiment": "negative"}, {"name": "fujifilm", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - Regenxbio Inc:\n* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES\n* REGENXBIO-UNDER TERMS REGENXBIO GAINS GUARANTEED CAPACITY FOR SUPPLY OF NAV AAV DRUG SUBSTANCE MANUFACTURED UNDER CGMP AT LARGE SCALE FOR THREE YEARS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T05:49:00.000+02:00", "crawled": "2018-01-24T15:38:43.000+02:00", "highlightTitle": ""}